JERUSALEM, November 28, 2016 /PRNewswire/ --
Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage
biopharmaceutical company focused on developing drugs based on its
proprietary Accordion Pill™ platform technology, announces it has
entered into an agreement with the Michael J. Fox Foundation for
Parkinson's Research (MJFF) to support patient recruitment and
retention support for the Intec Pharma's pivotal Phase III clinical
trial of its lead product candidate, the Accordion Pill
Carbidopa/Levodopa, or AP-CD/LD, for the treatment of Parkinson's
disease symptoms in advanced Parkinson's disease patients, which
began enrolling participants in April
2016.
MJFF is the largest non-profit funder of Parkinson's research
with a mission to accelerate the development of new therapies and a
cure for Parkinson's disease. Previously, the foundation supported
Intec Pharma with a $705,000 grant to
fund a pre-clinical study of AP-CD/LD.
"We are honored and pleased to collaborate with the foundation
on our Phase III trial recruitment activities," said Zeev Weiss, Intec Pharma's Chief Executive
Officer. "MJFF is one of the most well-respected research
organizations dedicated to the development of improved therapies
for Parkinson's patients. The foundation's long-term experience in
the field and close connections with the patient community are
especially valuable and will further support and enhance the
conduct of our Phase III study for the benefit of the entire
patient population."
"Additional options to treat the motor symptoms of Parkinson's
would have a significant impact on the millions living with this
disease," said Catherine Kopil, PhD,
MJFF director of research partnerships. "Leveraging our
Foundation's tools and best practices to encourage participant
enrollment in Intec Pharma's AP-CD/LD study will accelerate testing
of this potential therapy."
About Intec Pharma Ltd.
Intec Pharma Ltd. is a clinical stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline currently includes three product
candidates in clinical trial stages: Accordion Pill
Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the
treatment of Parkinson's disease symptoms in advanced Parkinson's
disease patients, currently in Phase III, Accordion Pill Zaleplon,
or AP-ZP, which is being developed for the treatment of insomnia,
including sleep induction and sleep maintenance, and an Accordion
Pill that is being developed for the prevention and treatment of
gastroduodenal and small bowel ulcers induced by Nonsteroidal
Anti-Inflammatory Drugs. In addition, an Accordion Pill for
cannabinoid therapies (AP-CBD/THC) will enter Phase I clinical
trial in the first quarter of 2017.
About The Michael J. Fox Foundation for
Parkinson's Research
As the world's largest non-profit funder of Parkinson's
research, the Michael J. Fox Foundation is dedicated to
accelerating a cure for Parkinson's disease and improved therapies
for those living with the condition today. The Foundation pursues
its goals through an aggressively funded, highly targeted research
program coupled with active global engagement of scientists,
Parkinson's patients, business leaders, clinical trial
participants, donors and volunteers. In addition to funding
more than $600 million in research to
date, the Foundation has fundamentally altered the trajectory of
progress toward a cure. Operating at the hub of worldwide
Parkinson's research, the Foundation forges groundbreaking
collaborations with industry leaders, academic scientists and
government research funders; increases the flow of participants
into Parkinson's disease clinical trials with its online tool, Fox
Trial Finder; promotes Parkinson's awareness through high-profile
advocacy, events and outreach; and coordinates the grassroots
involvement of thousands of Team Fox members around the world.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company's control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking
statements are described in the sections titled "Risk Factors" in
the company's filings with the Securities and Exchange Commission,
and include the following: the company's ability to develop and
commercialize its product candidates and obtain additional
financing necessary therefor; the length, cost and uncertain
results of the company's clinical trials; the potential of adverse
side effects or other safety risks that could preclude the approval
of the company's drug candidates; the availability of reimbursement
from government authorities and health insurance companies for the
company's products; the impact of product liability lawsuits; and
the influence of extensive and costly government regulation.
Contacts:
Zeev Weiss
Chief Executive Officer
Intec Pharma
+972-(2)586-4657
zeev@intecpharma.com
Anne Marie Fields
Senior Vice President
LHA
+1-212-838-3777
afields@lhai.com
SOURCE Intec Pharma Ltd.